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Deconvoluting the mode of action of natural products and drugs remains one of the biggest challenges in
chemistry and biology today. Chemical proteomics is a growing area of chemical biology that seeks to
design small molecule probes to understand protein function. In the context of natural products,
chemical proteomics can be used to identify the protein binding partners or targets of small molecules
in live cells. Here, we highlight recent examples of chemical probes based on natural products and their
application for target identiﬁcation. The review focuses on probes that can be covalently linked to their
target proteins (either via intrinsic chemical reactivity or via the introduction of photocrosslinkers), and
can be applied “in situ” – in living systems rather than cell lysates. We also focus here on strategies that
employ a click reaction, the copper-catalysed azide–alkyne cycloaddition reaction (CuAAC), to allow
minimal functionalisation of natural product scaﬀolds with an alkyne or azide tag. We also discuss
‘competitive mode’ approaches that screen for natural products that compete with a well-characterised
chemical probe for binding to a particular set of protein targets. Fuelled by advances in mass
spectrometry instrumentation and bioinformatics, many modern strategies are now embracing
quantitative proteomics to help deﬁne the true interacting partners of probes, and we highlight the
opportunities this rapidly evolving technology provides in chemical proteomics. Finally, some of the
limitations and challenges of chemical proteomics approaches are discussed.1 Introduction
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Natural products (NPs) have always been the inspiration for
the development of drugs and a source of tools to elucidate
cellular mechanisms. Drug discovery typically takes one of twoNat. Prod. Rep., 2016, 33, 681–708 | 681
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View Article Onlineapproaches: a target-based approach, where a compound is
developed to target a particular enzyme, and phenotypic
screening, where libraries of small molecules are screened
against live cells with a phenotypic read-out. A target-based
approach has the advantages that mode of action is, in prin-
ciple, known right from the outset, enzyme assays are typically
reliable and easy to perform, and compound design is oen
aided by structural biology. Phenotypic screening, on the other
hand, already takes issues such as cell uptake and eﬄux into
account, and non-specic cytotoxicity is more easily assessed.
For the phenotypic approach in particular, it is very challenging
to discover and validate the mode of action of a compound. An
added complexity is that compounds may have diﬀerent modes
of action in diﬀerent organisms or contexts, or may have
pleiotropic eﬀects.
Chemical proteomics is a rapidly evolving area of chemical
biology that draws on synthetic chemistry to generate probes
that inform on small molecule mode of action and protein
function. In the context of understanding the mode of action of
NPs and other small molecules, chemical proteomics primarily
provides information on the proteins a compound interacts
with. Chemical proteomic strategies for NP target identication
were reviewed in 2010 (ref. 1 and 2) and several reviews since
have touched on the diﬀerent approaches for target identica-
tion, of natural products, drugs and other molecules of
interest.3–5 Here we aim to survey and analyse studies from the
last ve years on chemical proteomics technologies for mode of
action, focusing on the following aspects: natural products,
‘discovery’ chemical proteomics (i.e. where the mode of action
and binding partner of the NP is unknown at the outset), in situ
approaches using covalent or photoprobes, two-step labelling
protocols that exploit bioorthogonal ligation chemistry, and
nally the advantage that can be taken of recent advances in
quantitative mass spectrometry-based proteomics methods. We
dene ‘in situ’ chemical proteomics as labelling with a ‘free’
probe in living cells, to distinguish it from classical aﬃnityMegan H. Wright received her
MSc in Natural Sciences
(Chemistry) from the University
of Cambridge in 2008, and then
studied for an MRes and PhD
(received 2013) in Chemical
Biology at Imperial College
London with Prof. Edward Tate.
She is currently a Marie Curie
Fellow hosted in the lab of Prof.
Stephan Sieber in the Techni-
sche Universita¨t Munich. Her
research interests include chem-
ical tools for studying post-translational modications, and the
development of photoaﬃnity and activity-based probes to under-
stand host–pathogen interactions and cancer.
682 | Nat. Prod. Rep., 2016, 33, 681–708chromatography (where lysates are incubated with resin func-
tionalised with the NP of interest and binding partners
retained, whilst non-binders are washed away), or incubation of
cell lysates with probes. Whilst aﬃnity chromatography has
been widely and, in some cases, very successfully applied for
target identication, it suﬀers from several disadvantages: weak
but true binders are oen missed (false negatives), the in vitro
setting is more articial than applying a probe in live cells (and
therefore potentially prone to false positives), and the ‘modi-
cation’ to the probe is large and may perturb protein binding.
Incubation of a free probe with lysates avoids some of these
issues but not the articial setting; approaches that apply
a probe in situ have the signicant advantage of being more
biologically relevant. However, it is generally accepted that in
order to be used in situ, the probe should be functionalised to
covalently link with binding partners. This can be accomplished
by incorporating either an intrinsically chemically reactive
group or a photoreactive group within the probe structure.
We will rst cover some general points on probe design,
validation and chemical proteomics workows. The second part
of the review covers recent case studies and we conclude with
a discussion on the advantages, limitations and challenges of
these approaches.1.1 Two-step activity and aﬃnity-based protein proling
1.1.1 Chemical proteomics and bioorthogonal ligation
chemistry. In situ chemical proteomics approaches take a small
molecule of interest and create a probe by functionalising it
with (1) a tag that will allow downstream analysis and, if
necessary, (2) a handle to stabilise the interaction between the
molecule and its protein binding partner (Fig. 1). This second
handle could be a photoreactive or intrinsically chemically
reactive moiety. In some cases it is possible to directly attach
a uorophore or biotin aﬃnity group in place of the tag;
however, a two-step tag-then-capture approach is becoming
increasingly popular. Two-step methods take advantage ofStephan A. Sieber studied
chemistry at the University of
Marburg, Germany. He did his
graduate studies in the labs of
Prof. Marahiel, University of
Marburg and Prof. Christopher
T. Walsh at Harvard Medical
School, Boston. He then joined
the group of Prof. Benjamin
Cravatt for his postdoctoral
work. In 2006 he started his
independent research career at
the University of Munich (LMU),
Germany and in 2009 was appointed full professor at Technische
Universita¨t Munich. His research focus is chemical biology and
chemical proteomics with emphasis on the reactivity of natural
products and their dedicated targets in prokaryotic and eukaryotic
cells.
This journal is © The Royal Society of Chemistry 2016
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View Article Onlinebioorthogonal ligations, highly chemoselective reactions that
take place under physiological conditions between two partners
– probe-bound protein and uorophore for example – in high
yields and with high specicity.6 These reactions enable the tag
incorporated into the molecule of interest to be very small: for
example, a terminal alkyne, azide or cyclopropene. This
approach minimises the alteration to the structure of the small
molecule and therefore reduces the chances that such func-
tionalisation will perturb binding to the target protein, as well
as preserving as much as possible physicochemical properties
so that cellular uptake is relatively unaﬀected and the probe can
be applied in the context of a live cell. The most widely used
bioorthogonal ligation is the copper-catalysed azide–alkyne
cycloaddition reaction (CuAAC) between an alkyne and azide.7,8
These two functional groups are relatively easy to introduce
synthetically, small, inert in biological contexts and the reaction
is robust. The main disadvantage of CuAAC is that it is limited,
largely, to use in lysates and xed cells because the copper
catalyst is toxic. However, for most identication strategies such
toxicity is not a problem: the probe is applied in live cells (‘in
situ’), the cells lysed and CuAAC carried out in lysate. CuAAC
also denatures and, sometimes, causes protein aggregation and
precipitation, which may make it incompatible with some
downstream applications, although some eﬀorts have been
made to optimise reagents to reduce this eﬀect.9 Two-step
protocols also allow the type of label introduced to be easily
varied; for example, a biotin or FLAG group can be introduced
for aﬃnity enrichment of tagged proteins and subsequent
identication by standard proteomic workows, or a uo-
rophore can be attached for visualisation in SDS-PAGE gels or
for imaging in cells (Fig. 1). Alkynes have emerged as preferred
tags due to their small size and the empirical observation thatFig. 1 Compound-centric chemical proteomics approach for identifying
the structure of the NP, is added to live cells and binds to its target prote
group) with the target protein. Cells are lysed and samples subject to co
rophore or aﬃnity label for downstream analysis.
This journal is © The Royal Society of Chemistry 2016having the azide on the labelling partner during CuAAC some-
times results in lower background.10–12 It is worth noting that
removing excess probe can sometimes be important for eﬃ-
ciency of CuAAC and can be accomplished by washing cells or
precipitating lysates. More importantly, unreacted CuAAC
labelling reagent must usually be removed before aﬃnity
enrichment analysis, since excess reagent can bind to the beads
and prevent eﬃcient pull-down of labelled proteins. This
introduces an extra clean-up step, usually protein precipitation,
and any additional steps in a complex workow can introduce
variability. Therefore, in some cases, direct labelling may have
advantages: for example, in labelling of secreted proteins, where
cell permeability of probes is less of a concern. Due to its wide
applicability compared to other bioorthogonal ligations, we will
focus here on CuAAC approaches for NP target identication.
1.1.2 Using intrinsic chemical reactivity. Use of CuAAC
chemistry and in situ labelling usually requires a second handle
in the molecule to stabilise the interaction with the target
protein. Pioneered by the Cravatt and Bogyo groups, activity-
based protein proling (ABPP) is now a well-established strategy
that uses probes containing electrophilic groups that react
covalently with enzyme active site nucleophiles.13,14 The reaction
is ‘activity-based’ because only those enzyme molecules that are
in an active conformation with an exposed active site can be
labelled with the probe. Some NPs are electrophilic, exerting
their biological eﬀect via this type of mechanism, and are
therefore readily amenable to an ABPP approach: the NP is
transformed into a probe itself (Fig. 1). Alternatively, if the NP is
thought to address a particular enzyme class, it can be screened
in competitive mode against promiscuous ABPP probes that
label that class (Fig. 2): the probe labels a dened set of proteins
and if the NP addresses one or more of these by binding to thethe targets of natural products (NPs). The probe is designed based on
in. It reacts covalently (via an electrophilic trap or a photocrosslinking
pper-catalysed azide–alkyne cycloaddition (CuAAC) to attach a ﬂuo-
Nat. Prod. Rep., 2016, 33, 681–708 | 683
Fig. 2 Principle of competitive ABPP. (a) An activity-based probe (ABP)
reacts with target proteins and can subsequently be detected by
CuAAC. (b) In the presence of a competitor, which may react with the
protein or may be non-covalent, the ABP cannot bind and a reduced
signal is detected.
Fig. 3 (a) Common electrophilic traps that react with nucleophilic
residues in proteins. (b) Commonly used photoreactive groups and
their reaction under UV light.
Natural Product Reports Review
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View Article Onlinesame site as the probe, a reduction in labelling of those proteins
is detected. The probe may be directly functionalised with
a detection tag or a two-step bioorthogonal ligation may be
used. In this review we refer to the approach of modifying a NP
to generate a probe as ‘compound centric’ and the approach of
screening against other probes as ‘competition-based’. It is
worth mentioning that not all reactive probes are strictly
speaking ‘activity-based’; as illustrated later, many probes
appear to not only react with active site nucleophiles but also
with other residues on enzymes, and other proteins. Whether
this reactivity is biologically relevant is very case- and, probably,
context-dependent.
Potential electrophilic traps include Michael acceptors, ring
strain scaﬀolds (b-lactones, b-lactams, aziridines, epoxides), a-
halo-carbonyls, isothiocyanates and many more (Fig. 3). Some,
such as b-lactones, are common motifs in natural products,
whereas others, uorophosphates for example, are not found in
nature but have been discovered or designed by chemists.
Tuning of electrophiles is an active area of research in chemical
biology and will undoubtedly yield new reactive motifs in the
future to expand the available toolbox.15
An ABPP approach is clearly most applicable to NPs that are
intrinsically electrophilic. However, many NPs bind their targets
non-covalently. An intriguing strategy, but one that has yet to be
widely explored in the eld, is that of ‘weaponising’ NPs with
reactive traps. Porco, Cravatt and co-workers recently reported
the synthesis of a b-lactone-functionalised derivative of the NP
rocaglate, which was shown by competitive ABPP to target
serine hydrolases.16 Such functionalisation of a NP has the
potential to signicantly alter its biological targets; however,
even if this is the case, it may lead to new and unexpected useful
tools for probing cellular function.
1.1.3 Photoaﬃnity labelling. Amore intuitive and unbiased
strategy for identifying the binding partners of unreactive NPs is
to use photoaﬃnity labelling (PAL). PAL makes use of photo-
reactive moieties that are inert under standard synthetic
chemistry and biological conditions but can be activated by UV
light, generating highly reactive transient species that crosslink
the probe to whatever molecule is in close proximity – including684 | Nat. Prod. Rep., 2016, 33, 681–708presumably the protein binding partner. Commonly used PAL
groups are benzophenones, aryl azides and alkyl or aryl dia-
zirines (Fig. 3). They all have their advantages and disadvan-
tages (reviewed in ref. 17), and a dearth of comparative studies
means that no consensus has yet emerged on how to choose one
over the other; indeed the choice of photocrosslinker seems to
be highly context dependent.18 There has been a recent resur-
gence of interest in alkyl diazirines, paralleled by improvements
in synthetic routes to access building blocks,19 due to their
small size, unbiased reactivity, and the relatively undamaging
wavelengths required for their activation.
1.2 Design and validation of probes
1.2.1 Probe design. Designing probes based on NPs in the
absence of any information on the potential targets or origin of
bioactivity is very challenging, and is compounded by the
structural complexity of many NPs and the necessity of devel-
oping total syntheses to access them. Even small tags and
handles such as alkynes or diazirines can perturb bioactivity
and binding if installed in the ‘wrong’ position. However, there
is almost always scope for modifying a NP without drastically
changing its mode of action and in this context structure–
activity relationship information can be very helpful. An alter-
native approach is to generate multiple probes with tags intro-
duced at diﬀerent positions. The synthesis of tag/handle-
modied NPs is highly dependent on the NP in question andThis journal is © The Royal Society of Chemistry 2016
Review Natural Product Reports
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View Article Onlinethe reader is referred to a recent review on the topic.20 Here, we
will instead illustrate aspects of probe design throughout with
reference to examples.
1.2.2 Intrinsic reactivity of alkynes. An aspect of probe
design worth discussing is the potential reactivity of alkynes
themselves. Terminal alkynes are found in several mechanism-
based inhibitors of enzymes. One example is the inhibition of
FAD-dependent enzymes by N-propargylamines: in the case of
monoamine oxidases, the FAD cofactor, which is covalently
bound to the enzyme active site via cysteine, oxidises the
N-propargylamine of the bound inhibitor, and subsequently
covalently attacks it (Fig. 4); this approach was used to develop
activity-based probes for this class of enzymes, which are
important for neurological functions due to their roles in
oxidative deamination of neurotransmitters.21 Similarly,
terminal alkynes can act as mechanism-based inhibitors of
p450 enzymes: oxidation of aryl acetylenes by the enzyme
generates a highly reactive ketene, which is rapidly attacked by
adjacent enzyme nucleophiles. Alternatively, alkyl acetylenes
can be oxidised to generate Michael acceptors. Again, such
a strategy has been exploited for the design of ABPs for
p450s.22,23 Finally, Ovaa et al. showed that an N-propargyl amide
functionality attached to ubiquitin reacted selectively with the
active site cysteine of deubiquitinating enzymes; furthermore,
they showed that N-propargyl amides appended to otherFig. 4 Reactive alkynes. (a) Mechanism-based inhibition of FAD-depende
cytochrome p450 enzyme by aryl alkynes or (c) alkyl alkynes.22,23 (d) Inh
This journal is © The Royal Society of Chemistry 2016scaﬀolds also targeted the active site cysteines of other prote-
ases highly selectively.24 So although alkynes are considered
highly bioorthogonal in most contexts, they can be rendered
reactive by enzymes or can react directly – usually aided by
binding in an enzyme pocket. The extent to which alkynes react
or are destroyed in living cells is currently unknown, since such
reaction results in removal of the detection tag.
1.2.3 Probe validation. Probes are typically validated by
direct comparison with the NP of interest in bioactivity assays.
Some eﬀect on bioactivity is not necessarily damning, since the
probe may be slightly more or less active than the NP but still
retain the same mode of action. Full proof of probe function
usually proceeds together with identication of putative
binding partners.1.3 Chemical proteomic workows
With probe in hand, the rst steps are typically small scale
labelling experiments to optimise time, concentration and
other conditions with a simple and quick read-out by SDS-PAGE
gel. A typical workow is the following: incubation of probe ‘in
situ’, photo-irradiation if appropriate, lysis, CuAAC ligation to
append a uorophore or other detection label, and analysis by
gel electrophoresis and uorescence scanning or Western blot
(to detect biotin). In-gel uorescence is quicker and cleanernt enzymes by propargyl aminemoiety.21 (b) Activation and inhibition of
ibition of proteases reported by Ekkebus et al.24
Nat. Prod. Rep., 2016, 33, 681–708 | 685
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View Article Onlinethan blotting for biotin, since there are no additional signals
from endogenously biotinylated proteins.11 Probe incubation
can alternatively be carried out ‘in vitro’ in cell lysates. Lysis
conditions are important in this case since the proteins must
remain in their functional and folded states in order to specif-
ically bind probe molecules. In situ approaches avoid this
potential concern and probes interact with a ‘native’ system.
The caveat to an in situ approach is that probe labelling of
proteins may be reduced by uptake issues or metabolism, and
cytotoxic probes can also cause problems by killing cells and
reducing the amount of material recovered. The latter problem
can usually be avoided by the use of short labelling times. An
alternative to this compound-centric strategy is to use
a competitive approach, where a NP of interest is used to
outcompete promiscuous probes that, for example, bind reac-
tive cysteines (see later). Competitive proling is usually applied
in vitro but has advantages in that it completely circumvents the
need to create a functional probe of each compound.
The conditions for probe incubation should clearly reect
the conditions of the biological assays being used to assess the
phenotype of the NP. For microorganisms the life stage or
growth stage and culture medium are important, since these
factors can impact uptake of compounds as well as the pro-
teome, and hence potential probe targets. Probe concentration
is also oen optimised. Electrophilic and photoreactive probes
usually label promiscuously at high concentrations; for
example, a recent paper by Cravatt and co-workers analysed the
labelling and targets of covalent kinase inhibitors converted
into activity-based probes by attachment of an alkyne tag: at
high concentrations of probe, labelling increased dramatically
and most bands could not be out-competed with parent
inhibitors – indicating non-specic reaction of probe with
proteins.25 The authors linked this increased labelling with
generic cytotoxicity. This study also illustrates how competition
with parent inhibitor can be used eﬀectively to assign proteins
as true or oﬀ-targets of a probe and rene the list of hits.
1.3.1 Proteomic identication of hits. To identify potential
hits of probes, experiments are performed with click chemistry
ligation to an aﬃnity label – usually biotin. Biotin binds
strongly to the protein streptavidin and its variants, allowing
enrichment or pull-down of labelled proteins onto streptavidin-
coated beads. Several groups have made use of customised
CuAAC reagents that incorporate both biotin and a uorophore
to enable simultaneous enrichment and facile detection.10,26,27
Enriched proteins can be eluted from the beads with denaturing
conditions for gel-based proteomics, or directly digested on-
bead with proteolytic enzymes. In a standard gel-based pro-
teomics workow, enriched samples are separated by gel, bands
or slices cut and digested, usually by trypsin. This approach has
been widely used historically and enables simple fractionation
of the sample, but suﬀers from contamination with environ-
mental proteins such as keratin and problems of bias – certain
proteins simply do not separate well on a gel. It is also diﬃcult
to quantify between samples. For these reasons, and enabled by
the improved sensitivity of mass spectrometers, gel-free
approaches are becoming increasingly common. Direct on-bead
digest is simple to perform, minimises environmental686 | Nat. Prod. Rep., 2016, 33, 681–708contamination and loss by reducing sample handling, and is less
biased than gel-based methods. In both cases, the resulting mix
of peptides can be analysed by standard shotgun LC-MS/MS
workows: peptides are separated by reverse phase chromatog-
raphy, and injected on-line into a tandemmass spectrometer for
measurement of ions, fragmentation and measurement of frag-
ments. Identication of proteins is carried out by soware
packages that compare the acquired spectra with spectra ob-
tained from in silico digest of proteins in a database (e.g. the total
proteome of the organism of interest). A vehicle control (oen
DMSO) is processed in parallel to provide a benchmark list of
proteins that bind non-specically to the beads. Hits are there-
fore identied as those proteins enriched over background.
1.3.2 Quantitative chemoproteomics. Related to the shi to
gel-free methods, recent chemical proteomic workows oen
incorporate quantication: for example, to compare vehicle
control and probe-incubated sample, competition with NP,
diﬀerent but related probes, biological conditions, replicates, and
so on. Popular quantication approaches include SILAC (stable
isotope labelling by amino acids in culture), iTRAQ (isobaric tag
for relative and absolute quantitation), TMT (tandem mass tag),
dimethyl labelling (DiMe), and label-free methods, such as spec-
tral counting and MS1 intensity-based methods.
Labelling approaches rely on the incorporation of isotopes
into peptides that are then mixed and analysed together in the
same LC-MS/MS run – peptides originating from diﬀerent
samples can then be distinguished in the mass spectrometer.
Label-free approaches compare samples that are analysed in
diﬀerent runs and have greatly improved in recent years with
the increasing sensitivity and resolution of LC-MS/MS as well as
advances in computational algorithms.28DiMe, iTRAQ and TMT
all involve chemical labelling of peptides29 and so have the
drawback that samples are only combined towards the end of
the chemical proteomics workow (Fig. 5a), therefore not
controlling for operator error or reproducibility of the protocol
to that point. Label-free suﬀers from the same drawback. SILAC
uses cultured cells where all proteins incorporate heavy, light or
medium amino acids and is therefore oen a popular choice
where it is applicable, since it allows samples (e.g.DMSO vehicle
control and probe) to be combined directly aer lysis (Fig. 5b).
One disadvantage of labelling methods like SILAC is that only
a limited number of samples can be combined; however,
a ‘spike-in’ approach can be used to overcome this: in this
approach a heavy standard sample is spiked into any number of
samples which are run separately and then the standard used
later in analysis for quantitative comparison.30 Considerations
in the choice of quantitative approach include: the complexity
and robustness of the workow (early mixing is an advantage),
the number of samples to be analysed and their origin (e.g.
vehicle control vs. probe vs. probe + competitor in a well-studied
cell culture line is easily done via SILAC, but for comparing tens
of clinical samples from diverse origins label-free may be more
appropriate), cost (some labelling methods use expensive
reagents), access to MS measurement time (label-free requires
each sample to be measured separately whereas in labelled
approaches samples are combined), and the MS instrument set
up (somemethods quantify at the parent ionMS1 level, others atThis journal is © The Royal Society of Chemistry 2016
Fig. 5 Quantitative approaches for chemical proteomics experiments. (a) In many label-based approaches (iTRAQ, DiMe.), samples are
processed separately, peptides are isotope labelled and then combined before mass spectrometry. (b) SILAC (stable isotope labelling of amino
acids in culture): cells are cultured with medium containing heavy or light isotope labelled amino acids; cells are treated diﬀerently (e.g. probe or
vehicle control/untreated), lysed and samples combined for all downstream analysis.
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View Article Onlinethe MS2 fragment ion level; reproducible chromatography and
instrument performance are particularly important for label-
free). For a full discussion of these issues the reader is referred
to several recent reviews.29,31
In chemical proteomics, a quantitative approach is a signi-
cant improvement on simply determining the presence or
absence of a protein in a particular sample and also allows for
greater exibility in the types of experiments that can be per-
formed. Some probes are highly specic, whereas others will
label many proteins, either due to promiscuity of the NP itself or
to limitations in the methodology (non-specic photoreactivity
or intrinsic reactivity). We and others have found that quanti-
fying the proteins enriched in the presence and absence of
a competitor such as the parent NP, for example, can provide
a lot of information on the putative hits of a probe.
1.3.3 Cleavable linkers in chemical proteomics. In the
majority of chemical proteomics experiments, binding of
a probe to a protein is inferred indirectly from the presence of
the protein (in fact its constituent peptides). This is because the
probe-modied peptide is likely le attached to the beads aer
digest (in gel-free approaches) and/or the peptides are not
separated well by HPLC or do not ‘y’ well in the mass spec-
trometer due to the bulky modication. However, direct iden-
tication of the modication site adds condence in the
assignment of the protein as a hit and provides additional
information about the putative binding site of the NP. Several
reagents for CuAAC have been reported that incorporate
a chemically, light, pH, enzyme or otherwise cleavable linker,
enabling selective release of the probe-modied peptide from
the beads, either with the total shotgun mix or in a separate
step. Such approaches also have the potential to reduce
contamination with non-specic background bead binders,
since proteins linked via the CuAAC reagent can be selectively
eluted. An early approach by the Cravatt lab termed TOPThis journal is © The Royal Society of Chemistry 2016(Tandem Orthogonal Proteolysis)-ABPP32,33 uses click reagent 1
(Fig. 6) incorporating a TEV (tobacco etch virus) protease
cleavable sequence that allows release of modied peptides
from the beads orthogonal to trypsin (the enzyme typically used
for the digest of proteins for MS). This reagent has been used
successfully for identifying cysteines modied by simple elec-
trophiles, such as an alkynylated iodoacetamide derivative.34
Diazobenzene-based reagents cleaved by treatment with
Na2S2O4 have been used to identify peptides incorporating
bioorthogonally tagged amino acids35 and trypsin protease
cleavable linkers were recently reported for the detection of
modication sites aer incorporation of alkyne-tagged fatty
acids or AMP analogues into proteins.36,37 Other reagents such
as vicinal diol linkers cleavable with sodium periodate have
been shown to reduce non-specic bead background38 but have
not yet been used for site identication. In general, few cleav-
able reagents have been applied to directly identify the site of
modication of NPs, probably because the structural
complexity, large size or lability of some NP probes is still
a limiting factor for their direct detection. We have also found
no report of direct detection of photolinked probe in a chemical
proteomic context. This is perhaps unsurprising since photop-
robes can in principle react at almost any position, with coin-
cident losses or rearrangements, yielding a very complex
problem for the search algorithms. Elution eﬃciency of the
intact proteins for gel electrophoresis is also reported to be poor
in some specic cases.39
1.3.4 Alternative enrichment/detection strategies. Biotin–
streptavidin is the most widely used enrichment system, due to
the strength of the interaction and the ready commercial
availability of reagents. However, this system does suﬀer from
background binding of endogenously biotinylated proteins that
can hinder detection of low abundance hits. An alternative
immunoaﬃnity method developed by the La Clair group usesNat. Prod. Rep., 2016, 33, 681–708 | 687
Fig. 6 Cleavable linkers for chemical proteomics. (a) Proteins enriched on resin e.g. by biotin–streptavidin, can be speciﬁcally released and then
analysed by MS (bottom), or digested on bead and then the modiﬁed peptide selectively released (top). (b) The isotopically-encoded protease
(TEV)-cleavable linker 1 for CuAAC and enrichment reported by Cravatt and co-workers.40
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View Article Onlinea coumarin label (immunoaﬃnity uorescent label, IAF), which
has a dual role as both a dye for cell imaging and an aﬃnity
label (Fig. 7).41,42 The specic antibody raised against the
coumarin epitope was shown to enable much cleaner immu-
noprecipitation than biotin–streptavidin in a BSA (bovine
serum albumin protein) test system.41 In the same study the
authors systematically examined CuAAC two-step labelling for
both biotin and IAF, with the azide and alkyne partners on
either the protein or the labelling reagent. They observed better
results with the protein-alkyne and IAF-azide combination, in
line with other studies.10–12 Interestingly, they noted that CuAAC
likely requires a covalent linkage between probe and target
protein for eﬀective enrichment, consistent with the denaturing
nature of the reaction: in applying their method to the NP gly-
cyrrhetic acid, if the coumarin label was ready-attached to the
probe, enrichment was possible, but two-step CuAAC did not
result in any enrichment. The IAF method has been applied to
identify the targets of the NPs seriniquinone43 and spirohex-
enolide A,44 amongst others.
Another approach that avoids biotin used a resin pre-
coupled to an alkyne for simultaneous click and enrichment of
an azide-tagged probe and its binding partners.45 The NP sca-
laradial 2 was functionalised with an azide, generating probe 3,
added to lysates or live cells, and then lysates incubated with the
alkyne-resin and click reagents (Fig. 7). The authors also directly
compared the new method with a purely in vitro method where688 | Nat. Prod. Rep., 2016, 33, 681–708scalaradial was directly attached to a resin and incubated with
lysates. Western blot conrmed that the previously reported
protein targets PRX1 and 14-3-33 were enriched by both
methods, and gel-based proteomics was used to identify
possible hits. Since scalaradial presumably binds its protein
targets non-covalently, this study suggests it may be possible to
optimise on-bead click to work without introducing a photo-
crosslinker or reactive moiety. However, controls performed in
the study showed that even in the absence of the reducing agent
required for the click reaction, some PRX1 and 14-3-33 were
detectable on the beads. These proteins are abundant and it
remains to be seen whether such an approach will work for low
abundance protein binders of a probe.
Sibbersen et al. recently reported a method combining click-
on-resin with a chemically cleavable diazobenzene linker to
facilitate release of enriched proteins.46 The amine- and azide-
functionalised diazo-unit was prepared by coupling to NHS-
activated sepharose resin (Fig. 7). The authors then applied
their approach in several test systems and in comparison with
either a standard biotin reagent or a diazo-biotin. They labelled
cells with a promiscuous electrophilic probe, 2-oxohex-5-ynal,
performed CuAAC and enriched proteins from lysates. All three
methods performed comparably, giving a similar pattern of
enriched proteins by Coomassie staining, with the diﬀerence
that the methods employing biotin also resulted in contami-
nation with signicant amounts of monomeric streptavidin. ItThis journal is © The Royal Society of Chemistry 2016
Fig. 7 Alternative enrichment methods to biotin–streptavidin. (a) IAF (immunoaﬃnity ﬂuorescent tag) reported by La Clair et al. for antibody-
based enrichment of probe-bound proteins. (b) Click-on-resin approach reported for the NP (natural product) scalaradial: scalaradial 2 is
functionalised to generate probe 3, which can be attached in turn by CuAAC to an alkyne-functionalised resin.45 (c) On-resin cleavable linker
reported by Sibbersen et al.46
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View Article Onlinewill be interesting to see whether this type of reagent proves
useful for chemical proteomic identication of protein binders
of a probe, and whether it proves possible to isolate non-cova-
lent probe–protein adducts.
Several methods for on-resin capture and release have also
been reported for peptides47,48 and, most recently, a silane-
based uoride cleavable linker was used to capture by strain-
promoted azide–alkyne cycloaddition (SPAAC) and then release
a small molecule and the enzyme chymotrypsin.49 Interestingly,
the released enzyme still retained 67% of its activity, consis-
tent with the milder nature of SPAAC compared to CuAAC.49
Biotin–streptavidin continues to be the most widely used
method for enrichment due to the strength of the interaction
and the ready availability of tools. Disadvantages include diﬃ-
culties in distinguishing non-specic streptavidin background
binders from true hits and challenges of identifying modiedThis journal is © The Royal Society of Chemistry 2016peptides. Numerous cleavable linkers have been reported to
tackle the second problem, but further advances in sample
preparation and bioinformatics workows will likely be needed
to expand their use. New technologies for enrichment are
always a welcome addition to the chemical proteomic arsenal.1.4 Target validation and mode of action
Once potential hits have been identied, the challenging tasks
of validating that they are true hits and linking binding to mode
of action begin. The rst problem is, relatively, simple and is
typically approached in several ways: if an antibody is available
or can be produced, labelling can be validated by Western blot
to show that the protein of interest is enriched aer CuAAC and
aﬃnity pull-down, or by immunoprecipitation and on-bead
CuAAC to install a label for detection. Alternatively, the proteinNat. Prod. Rep., 2016, 33, 681–708 | 689
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View Article Onlineof interest can be obtained recombinantly and labelling shown
on the puried protein or the protein in the context of the
overexpression system or spiked into a lysate. Labelling of an
isolated protein should be viewed with caution, however, as
some promiscuous probes label almost any protein in such an
articial environment. To demonstrate that probe binding is
dependent on a native, properly folded protein, a ‘heat’ control
in which proteins are rst heated with SDS to unfold them is
sometimes used. Access to the puried protein also provides the
opportunity to detect modication of the protein by the probe
via intact proteinMS or to digest and identify the binding site by
LC-MS/MS in a simpler system than the total enriched pro-
teome. Some probe–protein interactions can be studied by
biophysical methods, such as ITC (isothermal titration calo-
rimetry) and structural biology can also provide supportive
evidence, in the form for example of a crystal structure of probe-
bound protein. In the case of electrophilic probes, if the site of
modication can be identied, the amino acid residue involved,
e.g. Cys, Ser, can be mutated and the mutant protein analysed to
demonstrate that it no longer binds the protein of interest.
Demonstrating a direct link between NP binding to a protein
and mode of action of the NP can be very challenging. We will
illustrate the types of experiments used to tackle this problem
via specic examples. However, in general it is necessary to
apply many diﬀerent biological and chemical tools. For
example, in the context of the chemical proteomics experiment,
access to a structurally similar but biologically inactive NP and/
or probe is one approach that can help distinguish biologically
irrelevant but nonetheless genuine binders from those protein
targets that mediate the bioactivity. Small libraries of probes,
competition experiments, comparison of labelling in biological
systems where the phenotype of response diﬀers, chemical or
genetic knockout or knockdown, are all used to demonstrate
a link between binding and bioactivity.2 Fishing for targets: probe-centric
approaches
The following section discusses specic examples where CuAAC
together with in situ chemical proteomics has been used to
identify the binding partners of NPs.2.1 Early in situ approaches to identify the targets of
electrophilic natural products
2.1.1 Antibacterials. Prior to 2008, several ABPP-type
approaches for identifying the targets of electrophilic NPs were
reported, but studies typically used a uorophore or biotin
directly appended to the NP scaﬀold for detection. In 2008 we
took inspiration from the fact that several classes of important
antibiotics contain electrophilic b-lactone and b-lactam moie-
ties to develop “minimal”, alkyne-tagged ABPs from these
structures.50–52 Based on the b-lactam core, probes derived from
penicillin, aztreonam, cephalosporin (4) (Table 1), as well as
more simplied structures, were synthesised.50 Labelling with
these probes was proled by in-gel uorescence aer ‘in situ’
incubation with live bacterial cells and ‘in vitro’ incubation in690 | Nat. Prod. Rep., 2016, 33, 681–708cell lysates. Gel-based proteomics was used to identify several
penicillin-binding proteins as targets, as well as a b-lactamase
enzyme; this enzyme class is important for antibiotic resistance
in pathogenic bacteria. Recombinant overexpression and anal-
ysis of the catalytic activity of the b-lactamase conrmed that
the probes indeed inhibited the enzyme. Subsequent studies
used NP-inspired b-lactams to identify and compare enzymes in
antibiotic-resistant and sensitive strains of Staphylococcus
aureus, the cause of major MRSA-hospital-acquired infections.51
An identied MRSA-specic enzyme of unknown function was
further characterised as a likely metallo-b-lactamase by enzyme
assays, labelling with other tools specic for this enzyme class,
and competition of labelling with structurally-unrelated
protease inhibitors. Others have also applied b-lactam probes to
label the nucleophilic active sites of other enzyme classes such
as a specic lysosomal cysteine hydrolase,53 or have developed
cephalosporin C-based probes for imaging.54 Simplied probes
incorporating the 3-membered ring heterocycles oxirane, thiir-
ane and aziridine – other electrophilic motifs found in NPs –
were also shown to label proteins in situ in pathogenic bacteria
strains,55 further expanding the toolbox of probes for func-
tionally characterising enzymes in diverse systems.
One of the interesting targets of b-lactones identied in the
original study by Bo¨ttcher and Sieber was the caseinolytic
peptidase ClpP, whose activity is also linked to virulence.52
Some organisms, such as the human pathogen Listeria mono-
cytogenes, have two isoforms of ClpP, although most b-lactones
only label one. Zeiler et al. found that an alkynylated probe 5
based on the NP vibralactone labelled both isoforms, providing
a useful tool for biochemical and structural characterisation of
the ClpP system in Listeria.56,57 Our group has applied a similar
ABPP approach to identify the targets of the antibacterial NPs
showdomycin, rugulactone and hydroxyderricin. Showdomycin
is a nucleoside antibiotic with an electrophilic maleimide
moiety, a motif that commonly reacts with thiols. The probe 6
was synthesised by esterication of the free alcohol on the
ribose (Table 1) and applied in situ in diﬀerent pathogenic
bacteria.58 Proteins identied as targets by gel-based proteomics
were oxidoreductases and transferases, including the enzyme
MurA1, which catalyses an essential step in cell wall biosyn-
thesis. Another putative target, the reductase AhpC, was
recombinantly expressed, incubated with showdomycin, diges-
ted with chymotrypsin, and the peptides analysed by MS to
identify the binding site of the NP.
The NP rugulactone also contains two, presumably cysteine-
reactive, Michael acceptor systems. Nodwell et al. synthesised
a rugulactone probe 7 possessing an alkyne tag introduced on
the phenyl ring (Table 1) and a number of analogues with the
Michael system reduced to assess the role of these electrophilic
moieties.59 This is an example of a strategy used to link the
reactivity of a NP with protein binding and biological activity.
Application of in situ labelling and gel-based proteomics led to
the identication of a kinase, ThiD, involved in the biosynthesis
of thiamine, as one of the prominent hits. By showing that
antibacterial activity of the NP increased in thiamine-decient
medium, the authors provided evidence that the bioactivity is
related, in part at least, to ThiD inhibition. Battenberg et al. alsoThis journal is © The Royal Society of Chemistry 2016
Table 1 NP-inspired probes applied for target protein identiﬁcation studies using gel-based proteomics. Blue: modiﬁcation to introduce bio-
orthogonal alkyne tag
Natural product and structure of inspired probe Application, target(s) Ref.
Pathogenic bacteria
50
Penicillin binding proteins and b-lactamase identied as targets
Listeria monocytogenes
56
Multiple targets, including ClpP
Pathogenic bacteria
58
Targets: oxidoreductases and transferases, including the enzyme MurA1
Pathogenic bacteria
59
Targets: multiple, including kinase ThiD
S. aureus
60
Targets: multiple, including seryl-tRNA synthetase
Human breast cancer cells
62
Target: phosphoglycerate mutase 1 (PGAM1)
HepG2 liver cancer cells
63
Targets: multiple, including FAS (fatty acid synthase) and GAPDH
A549 cancer cells
67
Target: aldehyde dehydrogenase ALDH1A1
This journal is © The Royal Society of Chemistry 2016 Nat. Prod. Rep., 2016, 33, 681–708 | 691
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Table 1 (Contd. )
Natural product and structure of inspired probe Application, target(s) Ref.
HEK293 cells expressing TLRs
70
No proteomics – immunoaﬃnity methods identied binding to TLRs
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View Article Onlineapplied ABPP to identify the targets of the antibacterial chal-
cone 4-hydroxyderricin (probe 8, Table 1), another Michael
acceptor functionalised NP.60 Labelling in the cell lysates of
pathogenic bacterium S. aureus and gel-based proteomic iden-
tication facilitated by a diazobenzene-based cleavable linker to
release bound proteins from streptavidin resin, revealed seryl-
tRNA synthetase (STS) as one of the putative hits. The enzyme,
which is responsible for loading cognate tRNAs with serine, was
inhibited in vitro by the NP, suggesting it is a functionally
relevant target. However, identication of which of the ve
cysteines in STS is targeted by the probe proved diﬃcult,
suggesting that the compound may bind to multiple nucleo-
philic sites on the enzyme.
2.1.2 Cytotoxic and anti-cancer NPs. The ABPP approach
has also been applied to identify the targets of reactive NPs in
human cells. Inspired by NPs such as fumagillin and Lumanicin
C, Cravatt and co-workers synthesised a library of alkynylated
probes containing a reactive spiroepoxide moiety (e.g. 9, Table 1)
and screened them for cytotoxicity.61 The compound with the
highest cytotoxicity in a human breast cancer cell line was
further shown to label an additional band compared to biolog-
ically inactive probes in in situ proling experiments. This band
was identied as a glycolytic enzyme phosphoglycerate mutase 1
(PGAM1) by gel-based proteomics. Interestingly, PGAM1 was not
labelled in vitro by the probe, highlighting the value of applying
probes in a native in situ setting. The TOP-cleavable linker
approach described above was used here on partially puried
PGAM1 aer labelling of the enzyme in an overexpression
system, resulting in the identication of the region of modi-
cation by the spiroepoxide probe. A follow-up study claried the
site of modication as a lysine residue in the enzyme.62
b-Lactone probes have also been applied in human cells. The
b-lactone-containing anti-obesity drug orlistat is a derivative of
the NP lipstatin, an irreversible inhibitor of pancreatic lipase.Fig. 8 (a) Cytotoxic NP duocarmycin 11. (b) Seco-drug version of duoca
reported by Wirth et al.67
692 | Nat. Prod. Rep., 2016, 33, 681–708To investigate the putative targets of orlistat in cancer cells, Yao
and colleagues synthesised orlistat-like probes incorporating an
alkyne handle at diﬀerent positions (e.g. 10, Table 1).63 The anti-
proliferative activity and cellular eﬀects of probes were analysed
in HepG2 liver cancer cells, conrming their bioactivity was
comparable to that of orlistat, and then the probes were applied
in labelling experiments. Labelling patterns in vitro were
comparable to in situ, but background labelling was higher in
vitro. Gel-based proteomics identied known target FAS (fatty
acid synthase) as well as additional putative targets of the drug.
Western blotting with antibodies aer pull-down conrmed the
enrichment of several hits, and some of these were overex-
pressed and shown to be labelled by the orlistat probe. A Cys–
Ala mutant of identied putative target GAPDH, an abundant
housekeeping protein, was not labelled by the probe, indicating
probe labelling of this particular cysteine residue. GAPDH and
additional proposed targets of orlistat have yet to be linked to
mode of action of this drug, but at the very least orlistat-based
probes have revealed that the compound covalently reacts with
a number of cellular targets. In 2014, the Wenk and Yao groups
further applied orlistat probes to investigate the bactericidal
activity of the drug.64 Gel-based proteomics aer probe labelling
of Mycobacterium cell lysates revealed lipid esterases as targets.
Chemical proteomics can reveal unexpected modes of action
of NPs. Duocarmycins (e.g. 11, Fig. 8), a class of anti-tumour NP
from Streptomyces, are known to act by alkylation of DNA via an
electrophilic cyclopropane and derivatives use a seco-drug
structure where the cyclopropane is formed in situ from an
appended chloromethyl (Fig. 8).65 However, removal of the
indole DNA-binding unit, gave a compound that was still highly
cytotoxic, raising the possibility of alternative non-DNA related
targets.66 Wirth et al. synthesised a duocarmycin-inspired alky-
nylated probe 12 which retained cytotoxicity and labelled one
prominent protein aer in situ incubation with A549 cancerrmycin and activation mechanism. (c) Duocarmycin-inspired probe 12
This journal is © The Royal Society of Chemistry 2016
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View Article Onlinecells.67 In yet another example of such an eﬀect, the probe barely
labelled this band in cell lysates. Gel-based proteomics identi-
ed the protein as aldehyde dehydrogenase ALDH1A1. A follow-
up study applied additional probes lacking the DNA-binding
motif as well as those based on a bifunctional scaﬀold; these
probes also labelled ALDH1A1.68 Further crystallographic,
computational and biochemical studies of ALDH1A1 claried
the mechanism of inhibition and the binding site of duo-
carmycin-inspired compounds.69
Food-derived natural products with potential anti-inam-
matory properties are also interesting bioactive compounds. A
recent study looked at the isothiocyanate iberin, which was
identied from cabbage and onion extracts as an inhibitor of
inammation-mediating toll-like receptors (TLRs).70 As part of
this wider study, alkynylated probes (13, Table 1) were syn-
thesised and applied in situ. Target engagement was conrmed
using Western blot for TLRs aer enrichment of tagged
proteins, although additional targets of the iberin probes were
not identied by proteomics.2.2 Going gel-free and quantitative
A survey of the examples given above makes it clear that
although some reactive NPs are highly selective for a few targets,
many probes label multiple proteins. Distinguishing between
true hits related to bioactivity, hits that are irrelevant for
bioactivity but nonetheless genuinely labelled, probe-specic
oﬀ-targets, and background proteins from CuAAC or enrich-
ment, is not trivial. As discussed previously, the increasing
sensitivity and resolution of mass spectrometers, coupled with
the improvement in algorithms for analysing complex datasets,
has brought quantitative proteomics to the fore in chemical
biology. Gel-free approaches enable unbiased identication of
hits and quantication allows for far more sophisticated
experimental set-ups, including measuring binding in situ by
quantifying increasing concentrations of probe, comparing
across diﬀerent tissue or cell types, or quantifying response to
inhibitors or competitors. The following recent examples of NP
or NP-inspired probes highlight the use of gel-free and/or
quantitative proteomics to study NP mode of action.
2.2.1 Studies using label-free methods. Pyrethroids are
widely used insecticides derived from pyrethrins, botanical NPs,
and act by blocking voltage-gated sodium channels. Ismail et al.
developed a library of pyrethroid-inspired alkyne probes in
order to prole the cytochrome p450 (CYP) detoxifying enzymes
that may be involved in pyrethroid metabolism and resistance.71
Aryl-alkynes are known mechanism-based inhibitors of CYPs
(as described above) and probes incorporated an alkyne
warhead as well as a second alkyne for click chemistry (e.g. 14,
Table 2). Incubation of mouse liver microsomes with probes
and gel-based identication with semi-quantication by a gel-
free method revealed the prole of CYPs labelled. This was
followed up with gel-free analyses, which gave a similar list of
CYP targets, although their rank diﬀered compared to the gel-
based data. The semi-quantitative method used, emPAI (Expo-
nentially Modied Protein Abundance Index),72 is based on
coverage of the protein sequence and was used here to indicateThis journal is © The Royal Society of Chemistry 2016the relative abundance of diﬀerent enzymes. Importantly, the
gel-free approach enabled the identication of additional drug-
metabolising enzymes labelled by pyrethroid probes.
Several recent studies have used chemical proteomics to
prole the modication of proteins with the important antima-
larial drug artemisinin (ART). ART is a plant-derived natural
product with an unusual endoperoxide bridge (15, Fig. 9); this
feature is thought to be activated by iron species in the red blood
cells where the malaria parasite resides, generating reactive
radicals that can attack cellular structures or biomolecules.
However, the identities of modied proteins and the mode of
action of ART are not fully understood. Wang et al.73 and Ismail
et al.74 independently reported several alkyne- or azide-tagged
artemisinin probes (16–18, Fig. 9); these were incubated with
parasite cultures, proteins captured by CuAAC, enriched and
identied, with semi-quantication via emPAI scoring in both
cases. Wang et al. identied 124 enriched proteins and showed
that several of the enzymes were inhibited by activated artemisi-
nin in vitro; they further applied their alkynylated probe to study
the mechanism of ART activation (an open question in the eld)
using iron chelators or inhibitors of haem production, concluding
that haem is the dominant source of activation. Ismail et al.
applied azido- and alkynyl-probes to identify around 60 enriched
proteins; they also studied the eﬀect of free iron chelators,
observing some eﬀect on labelling but also noting that this was
not suﬃcient to explain ART modication of several proteins.
Wang et al. also applied their probe in a human cancer cell line,
since cancer cells have been proposed to be more susceptible to
ART treatment than normal cells. A third recent study (Zhou et al.)
also identied ART targets in cancer cells using an alkynylated
probe 19, similarly concluding that haem is the agent responsible
for ART activation.75 Together these three studies shed light on the
likely protein targets of ART in live cells and provide tools to probe
biological questions of the mode of action of this important drug.
Another label-free approach is spectral counting; this
method estimates protein abundance by counting the number
of MS2 spectra assigned to a particular precursor ion and hence
protein, although the method suﬀers from limited dynamic
range and can only accurately quantify abundant proteins in
a sample.76 Zheng et al. recently used spectral counting to
quantify the chemical proteomic targets of an alkyne-tagged
version of the NP cerulenin (20, Table 2).77 Cerulenin has been
proposed to inhibit palmitoylacyltransferase (PAT) enzymes,
which carry out the lipid modication of proteins known as
palmitoylation, and fatty acid synthases by reaction of the a-
keto-epoxide with active site cysteine residues. Zheng et al.
modied the terminus of the long aliphatic chain of the NP with
an alkyne, and carried out identication of targets of the cer-
ulenin probe in melanoma cells. They compared this with cells
pre-treated with cerulenin itself or another PAT inhibitor 2-
bromopalmitate in competition experiments. Several proteins
that responded to competition were indeed identied and
further experiments validated that two of these were palmitoy-
lated. The authors also proled the labelling pattern in lysates
from Hek293 cells transfected with diﬀerent members of the
DHHC family of PAT enzymes; however, mutation of the active
site cysteines of DHHC 3 and 4 did not abolish labelling,Nat. Prod. Rep., 2016, 33, 681–708 | 693
Table 2 NP-inspired probes applied for target protein identiﬁcation studies using gel-free and quantitative proteomics. Blue: modiﬁcation to
introduce bioorthogonal alkyne tag
Natural product-inspired probe Application, methods, target Ref.
Mouse liver microsomes
71
EmPAI quantitative proteomics
Targets: cytochrome p450 enzymes
Melanoma cells and Hek293 cells overexpressing PAT enzymes.
Quantication by spectral counting
77Multiple targets, including PATs, likely palmitoylated proteins
Trypanosoma brucei
80
Gel-based and gel-free iTRAQ
Targets: kinases, including TbGSK3short, TbCLK1 & 2
Human cancer cell lines
81
iTRAQ proteomics
Targets: multiple
Vibrio species
85
Dimethyl labelling proteomics
Targets: LuxS and LuxE, others
Liver cancer cell lines and mouse liver tissue
87
SILAC proteomics
Targets: multiple, including aldehyde dehydrogenases (esp. ALDH4A1)
and CES1 (metabolite target)
HL-60 leukaemia cells
89
SILAC proteomics
Targets: DERL1, CYB5B, TBXAS1
HeLa and HEK293 cancer cells
90
SILAC proteomics
Targets: multiple membrane-associated proteins and proteins involved in
lipid biosynthesis/metabolism
694 | Nat. Prod. Rep., 2016, 33, 681–708 This journal is © The Royal Society of Chemistry 2016
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View Article Online
Table 2 (Contd. )
Natural product-inspired probe Application, methods, target Ref.
HeLa cancer cells
91
Spike-in SILAC proteomics
Targets: multiple
RKO colon cancer cells
92
Peptide-centric approach; quantication based on isotopically-tagged,
UV-cleavable CuAAC reagents
Targets: multiple-reactive cysteines
Fig. 9 Antimalarial natural product artemisinin (ART, 15) and reported probes 16–19.73–75
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View Article Onlinesuggesting that the probe labels other sites and therefore is not
‘activity-based’.
Spectral counting was also used by Pratt and co-workers in
a study with alkynylated aspirin (21, Fig. 10).78Well known as an
anti-inammatory drug, aspirin acts in part as an acetylating
agent, covalently modifying key serine residues in cyclo-
oxygenase enzymes, but the identities of other potential acety-
lation targets were unknown. HCT-15 colorectal cancer cellsFig. 10 (a) The NP aspirin alkylates proteins. (b) Structure of aspirin-
based probes 21 that have been reported.78,79 (c) Cleavable linker 22 for
the detection of aspirin probe-acylated peptide sites.79
This journal is © The Royal Society of Chemistry 2016were labelled with aspirin probe and proteins identied by
a standard chemical proteomics workow. The authors per-
formed three replicates and used spectral counting and other
cut-oﬀ criteria to identify potential hits; acetylation was further
conrmed for several histone proteins.
2.2.2 Label-based approaches: quantication at the
peptide level. Apart from the bias of spectral counting towards
larger proteins and the diﬃculties of quantifying low abun-
dance hits, it is also challenging to dene a cut-oﬀ when faced
with a list of proteins and counts – to diﬀerentiate specic and
non-specic binders for example. This is particularly true when
dealing with probes that label many protein targets, as is the
case for the examples of cerulenin and aspirin discussed above.
Therefore, many recent studies have used alternative quanti-
cation methods. In an independent report, Wang et al. also
applied alkyne-modied aspirin probes to identify protein
targets of aspirin acetylation in cancer cells, but used quanti-
cation by label-based method iTRAQ.79 In iTRAQ, isotope
labelling is performed at the peptide level, in this case aer
peptide release by on-bead digest. Wang et al. also applied
a cleavable linker strategy to orthogonally release modied
peptides from the beads and simultaneously quantify sites of
aspirin acetylation. In this case, the novel CuAAC reagent 22
contained an acid cleavable linker (Fig. 10), so that following
on-bead digest and removal of most peptides, the modiedNat. Prod. Rep., 2016, 33, 681–708 | 695
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View Article Onlinepeptides could be easily cleaved with 5% formic acid. For the
1000 proteins quantied in the study, the modied site was
identied in roughly half of cases, providing high condence
for the identication of these proteins as true hits of the probe.
Although lysine was the main acetylated residue, the authors
also found evidence for modication of other side chains, such
as serine and threonine, although the high concentration of
probe used may mean that some of these are not physiologically
relevant – always a concern with chemical probes. Based on
their high condence hit list, Wang et al. predicted the path-
ways aﬀected by aspirin acetylation and showed that aspirin
induces autophagy and activates lysosomal function in cells.
Natural products with validated mode of action in one
organism are sometimes transferable to less well characterised
systems. In 2013, the Taunton et al. showed that the polyketide
NP hypothemycin, which is known to inhibit several human
kinases, is also active in Trypanosoma brucei, the protozoan
parasite that causes the disease Human African Trypanosomi-
asis (HAT).80 Hypothemycin contains an electrophilic Michael
system which reacts with the nucleophilic thiol of select
kinases. Taunton and colleagues created alkynylated probe
version 23 via semi-synthetic modication of the NP – by simple
replacement of a methyl ether with propargyl ether (Table 2). 23
had the same potency as the NP in parasite growth inhibition
assays and labelled multiple bands aer CuAAC. Only one clear
band at 43 kDa showed dose-dependent saturation of signal
intensity and could be out-competed by the parent NP, however,
in an elegant example of using a gel-based read-out to assess
specicity of probe labelling. Gel-based proteomics of the 43
kDa band revealed the kinase TbGSK3short as the dominant
target but several other kinases were also identied. Noting that
low abundance targets could be overlooked in proteomic anal-
yses given that the probe also labelled abundant proteins non-
specically, the authors next carried out gel-free, iTRAQ-based
quantitative chemical proteomics with samples incubated withFig. 11 (a) Andrographolide 24 and positions used to incorporate an
alkyne in various reported probes (see also Table 2).81,82 (b) Fluorogenic
probe reported by Yao et al.82 reacts to release a ﬂuorophore upon
attack by a nucleophilic cysteine residue.
696 | Nat. Prod. Rep., 2016, 33, 681–708their probe and increasing concentrations of the parent NP as
competitor. Competition curves were then plotted with the
quantied data for each protein, conrming TbGSK3short as
a strong hit, but also showing that the kinase TbCLK1/2 was in
fact more sensitive to modication by the NP. Follow-up
experiments showed that the isoform TbCLK1, and not CLK2 or
the more abundant kinase GSK3short, is likely the relevant
target for parasite death. This study is therefore a nice example
of how gel-free, quantitative proteomics combined with
competition experiments and followed up with careful valida-
tion can deconvolute the biologically-relevant targets of a NP.
Further lessons on the promiscuity of some reactive NPs and
the challenges of identifying the interaction responsible for
bioactivity are provided by the NP andrographolide (Andro 24,
Fig. 11), which has diverse anti-inammatory and anti-cancer
eﬀects. Two independent studies have developed probes for
Andro and applied them in diverse cancer cell lines.81,82 Andro
possesses an a,b-unsaturated g-lactone moiety and in the rst
study Wang et al. modied the pendant hydroxyl by esterica-
tion or replaced it with an amide for introduction of an alkyne
(25 and 26 Table 2).81 The amide probe gave far more intense
labelling in cancer cell lines, likely because the ester is hydro-
lysed, resulting in loss of the alkyne tag; in fact elimination of
the b-hydroxy group has been proposed to occur during reaction
with proteins. Aer iTRAQ quantication of replicate experi-
ments with the amide probe and ltering, the authors identied
75 possible hits, including one known target. Several hits were
conrmed by enrichment and Western blot. Two proteins were
then studied in more detail via overexpression and identica-
tion of cysteine residues as Andro binding sites. Finally, basedFig. 12 (a) Dimethyl labelling (DiMe) on peptide amines for quantita-
tive comparison of up to 3 samples. (b) Fimbrolide 27 and corre-
sponding probe 28.85
This journal is © The Royal Society of Chemistry 2016
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View Article Onlineon pathway analysis of identied proteins, the authors pre-
dicted that metastasis would be aﬀected by Andro treatment;
indeed, fairly low concentrations of Andro reduced migration
and invasion in HCT116 cells. The second report on Andro
probes took a diﬀerent approach to probe design. Taking
advantage of the susceptibility to elimination of any leaving
groups appended to the a,b-unsaturated g-lactone ring, the Yao
group attached uorogenic dyes at this position to provide
a rapid read-out of probe reaction for imaging studies.82 The
alkyne tag was instead attached to alcohol functionalities at the
other end of the molecule (Fig. 11). Gel-based proteomics
identied several hits; however, the authors also randomly
selected recombinant proteins and showed that almost all were
labelled by Andro in vitro. On this basis they concluded that
Andro is a highly promiscuous compound, consistent with the
study of Wang et al.
iTRAQ uses reporter ion quantication: this means that the
diﬀerent reagents used to label peptides are isobaric – the same
in mass – resulting in identical parent peptides which are
diﬀerentiable only aer fragmentation in the mass spectrom-
eter (so-called ‘reporter ions’ are released). An alternative to
iTRAQ for peptide-level mixing of samples is dimethyl labelling
(DiMe), where quantication is carried out at the parent ion
(MS1) level and which has the advantage of using inexpensive
reagents.83 DiMe works by isotopic labelling of free amines in
peptides via reductive amination with formaldehyde and
sodium cyanoborohydride, both available with heavy isotopes
incorporated such that peptides from diﬀerent samples diﬀer in
mass by >4 Da (Fig. 12a). A recent example from our lab used
DiMe quantication to deconvolute the targets of mbrolide
NPs. Fimbrolides such as 27 (Fig. 12b) are marine halogenated
furanones that inhibit bacterial quorum sensing, intercellular
communication via small molecules.84 Zhao et al. synthesisedFig. 13 Acivicin 29 and probes 30–33.87
This journal is © The Royal Society of Chemistry 2016alkyne-tagged variants of these halogenated furanones (e.g. 28,
Table 2) and applied them in live Vibrio cells – bacteria well-
studied for their ability to engage in QS-induced biolumines-
cence.85 Aer assessing the panel of probes for their ability to
reduce bioluminescence in the bacteria, the mbrolide and cor-
responding probe showing the best andmost comparable activity
were selected for further studies. DiMe was used to quantitatively
compare proteins enriched from samples treated with (1) DMSO
vehicle, (2) probe 28, and (3) probe 28 following addition of
excess NP 27 (competition). The competition experiment was
used to select protein targets shared by the probe and NP, which
included QS-related enzymes LuxS and LuxE. Binding of the
probe to cysteine residues was further shown in these two cases
via MS/MS analysis of digested recombinant protein. Several
other targets were also identied, suggesting that mbrolides act
via multiple pathways in bacteria.
2.2.3 Label-based approaches: SILAC. Protein quantica-
tion by SILAC, where samples can bemixed at the lysate stage, is
very attractive because it does not suﬀer from the problem that
samples are combined at the peptide level – which is the case in
methods such as iTRAQ and label free described above.
Acivicin (29 Fig. 13) is a NP with broad bioactivity that has
been studied as a potential anti-cancer agent. Several enzymes
had been identied as potentially inhibited by acivicin, but no
unbiased and global analysis of potential protein targets had
been carried out. The 4-chloroisoxazole moiety reacts with
nucleophilic side chains in an addition–elimination reaction.
An initial study by Orth et al. developed ACV-inspired 4-chloro-
and 4-bromo-isoxazole probes and applied them in gel-based
chemical proteomics analyses of potential targets in bacteria,
identifying several dehydrogenases as likely targets.86 Kreuzer
et al. extended this approach in a liver cancer cell line and
mouse tissue.87 Since acivicin is a small compound with several
potential sites for modication, Kreuzer et al. generated several
diﬀerent probes 30–33 to maximise the chances of identifying
relevant targets. Gel-based chemoproteomics identied alde-
hyde dehydrogenases amongst the targets in mouse liver lysate
and HepG2 human cells, and subsequent gel-based SILAC
experiments, including quantication of competition with the
NP, conrmed the hits in the latter. Interestingly, aer pro-
longed incubation of cells with probe 30, a new target, identied
as carboxylesterase 1 (CES1), appeared. Recombinant CES1
itself was not labelled by 30, however, although it was active,
suggesting that a probe metabolite is the responsible agent.
Follow-up in vitro studies and siRNA knockdown in human cells
conrmed CES1 and one aldehyde dehydrogenase, ALDH4A1,
as proteins important for viability.
The marine diterpene eupalmerin acetate (EuPA) shows
activity against cancer cell lines and in amouse tumour xenogra
model.88 The mode of action of EuPA is presumed to arise from
reaction of the exocyclic alkene with nucleophilic residues in
proteins. Romo and colleagues explored the use of rhodium(II)-
catalysed C–H amination chemistry to remodel and functionalise
the structures of complex NPs.89 EuPA was derivatised with an
alkyne tag and the resulting probe 34 (Table 2) applied in HL-60
leukaemia cells; many bands were labelled but only a few of these
could be outcompeted by the parent NP. To identify theNat. Prod. Rep., 2016, 33, 681–708 | 697
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View Article Onlineresponsive proteins, SILAC experiments were used to (a) compare
heavy and light EuPA-probe-treated cells, and (b) compare cells
treated with either probe alone or rst treated with parent NP and
then probe. Duplicate runs and a gel-free protocol were used, and
hits selected on the basis of an enrichment of1.0 in experiment
(a), and a high ratio of probe/competition in experiment (b). The
three most promising hits were further validated by over-
expression and labelling in Hek293 cells.
A few natural products already contain terminal alkynes that
are potentially usable as tags. Nickel et al. devised a total
synthesis of callyspongynic acid (35, Table 2) to test its potential
as a probe.90 Like other polyacetylenes, callyspongyinic acid is
lipid-like and was therefore hypothesised to act on lipid sig-
nalling pathways in the cell. In situ labelling in human cell lines
revealed a number of bands and gel-free proteomics with SILAC
in triplicates was used to quantify enrichment in NP-treated
cells compared to a vehicle control. The authors note the high
reproducibility of SILAC ratios between replicates and that the
majority of the 400 proteins quantied across all three repli-
cates showed no enrichment, indicative of the very high sensi-
tivity of modern MS instruments for detecting background
binders on the enrichment beads. Gene ontology analysis of
hits revealed that almost half were enzymes that could poten-
tially bind callyspongynic acid or a metabolite for further
metabolism or degradation. Non-enzyme putative targets were
also identied and the authors speculate that these, mostlyFig. 14 Benzophenone (Bpa)-containing photoprobes. (a) Probe 38 bas
698 | Nat. Prod. Rep., 2016, 33, 681–708membrane, proteins may be enriched due to membrane
perturbations of the NP.
As mentioned above, standard SILAC is limited by the
available isotopically labelled amino acids to direct comparison
of three samples mixed together, and cannot be used to analyse
tissue samples, for example. However, use of a ‘spike-in’ stan-
dard can sometimes overcome these limitations. In spike-in
SILAC a single reference sample is produced by SILAC labelling
and then spiked into any number of diﬀerent experimental
samples.30 Provided the spike-in reference has appropriate
coverage of the proteome in the experimental samples, the
reference can then act as an internal standard, allowing
comparison across all samples, which can be produced inde-
pendently and from diﬀerent sources. Spike-in SILAC was used
by the Tate group to identify the targets of the NP zerumbone,
for quantifying concentration-dependent competition of alkyne
probe with the parent NP.91 The cyclic sesquiterpene zer-
umbone, which has diverse anti-inammatory activities,
possess two electrophilic Michael acceptor systems with
potential protein reactivity and so a probe 36 was synthesised
with an alkyne attached at a distal site (Table 2). A large batch of
SILAC heavy cells were labelled with the probe, and subsequent
triplicate samples in standard cell culture medium were
prepared with probe and increasing concentrations of parent
NP. Statistical analysis of the enrichment ratios allowed a subtle
analysis of the hits to identify those where probe binding wased on vancomycin.94 (b) Probe 39 based on pretubulysin.27
This journal is © The Royal Society of Chemistry 2016
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View Article Onlinemost robustly out-competed. The prole of high condence hits
revealed proteins with diverse biological functions, underlining
the likely pleiotropic mode of action of zerumbone.
2.2.4 Alternative quantication approaches. All the studies
discussed above performed enrichment of proteins following
CuAAC and then digested these for shotgun proteomics. In
select cases, orthogonal release of the modied peptide was also
applied to identify the site of reaction of the probe. However, an
alternative approach is to digest proteins rst and then carry out
CuAAC and enrichment of peptides with a cleavable reagent.
Although this results in a loss of information – since the
majority of the peptides from a particular protein are not
present – it is one strategy for focusing on the site of modi-
cation, and enrichment of peptides is also likely to be less
biased and more eﬃcient than enrichment of proteins. A recent
study by Yang et al. applied such a peptidic site-centric
approach to identify modication of proteins by the electro-
philic lipid 4-hydroxy-2-nonenal (HNE).92 HNE is one of
a number of endogenously produced lipid-derived electrophilesFig. 15 Diazirine-based photoprobes. (a) Probe 41 based on a fungal dep
43 and photo-Pro 44 incorporating diazirines. PG ¼ protecting group. (
This journal is © The Royal Society of Chemistry 2016which modify proteins and thereby mediate responses to
oxidative stress. In 2008, an azido-tagged HNE analogue was
used to identify potential targets, including several heat shock
proteins, by gel-based proteomics.93 The follow-up study from
Yang et al. then applied the peptide-centric approach with
alkyne-tagged HNE 37 (Table 2) and novel isotopically-tagged,
UV-cleavable CuAAC reagents (“Az-UV-biotin”).92 37 was incu-
bated with RKO colon cancer cells, cells lysed and proteins
digested with trypsin; Az-UV-biotin reagents were then reacted
with peptide mixtures, samples enriched on streptavidin beads
and released by irradiation with UV light. The isotopic tagging
in the Az-UV-biotin reagents facilitated identication of the
peptides and quantication. As an example of how this could be
applied, Yang et al. analysed pulse-chase type experiments in
which cells were labelled with 37, and then incubated in HNE-
free medium for diﬀerent periods of time. Using this approach
they were able to measure the dynamics of HNE modication in
live cells.sipeptide NP 40.96 (b) Amino acid analogues photo-Leu 42, photo-Met
c) Peptidomimetic probe 45.98 (d) Staurosporine photoprobe 46.101
Nat. Prod. Rep., 2016, 33, 681–708 | 699
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View Article Online2.3 Photoaﬃnity labelling
This review has thus far focused on NPs that are intrinsically
electrophilic, of which there are many examples. However, most
NPs act by non-covalently binding their targets. Photoaﬃnity
labelling (PAL) is a technology in which photoreactive groups
are introduced into a probe so that a covalent link can be made
between the probe and its target. PAL has been experiencing
a resurgence in recent years, fuelled by the development of
CuAAC chemistry allowing the introduction of minimal tags for
target shing. Benzophenone, aryl azide, aryl and alkyl dia-
zirines are the most commonly used PAL groups (Fig. 3).17,18
Benzophenone (Bpa) is a historically popular PAL group due
to its stability towards chemical synthesis. Bpa–alkyne probes
(e.g. 38) of the glycopeptide antibiotic vancomycin was used to
identify potential protein binders in pathogenic bacteria
(Fig. 14).94 Eirich et al. synthesised several probes with the Bpa
and alkyne moieties in diﬀerent positions and applied them
both in vitro and in situ. Two distinct protein hits were identied
by gel-based proteomics in antibiotic-resistant S. aureus and E.
faecalis as bifunctional autolysin (ATL) and a peptide ABC
transporter respectively. Both hits were subsequently validated
by recombinant expression and labelling, and the degradation
of peptidoglycan by ATL shown to be inhibited by vancomycin.
Eirich et al. reported another example of a Bpa photoclick probe
39, based on pretubulysins, compounds derived from the NPs
tubulysins (Fig. 14).27 Structure–activity relationships aided
probe design, and the bulky Bpa was incorporated at a position
known to be tolerant to modications. Despite this careful
design, there was a signicant drop in activity. However,
labelling was performed in HeLa cancer cells and one particu-
larly prominent band was shown to respond to competition;
this band was identied as tubulin, the known target of tubu-
lysins. The authors further applied their probe for uorescence
imaging in cells.Fig. 16 (a) Acyl homoserine lactone 47 and reported probes 48–50.104
700 | Nat. Prod. Rep., 2016, 33, 681–708The bulky size and possible propensity of Bpa to react pref-
erentially with methionine95 are disadvantages. Other PAL
linkers such as aryl azides are best excited by short wavelengths
of light (typically 265 to 275 nm), potentially damaging proteins
which absorb light in this range. The rst example of incorpo-
ration of the small alkyl diazirine group into a NP was reported
in 2007 by the Taunton group.96 In this study, a probe version of
a fungal cyclodepsipeptide (HUN-7293, 40), which was known to
inhibit cotranslational translocation, was designed. The probe,
41, contained an alkyl diazirine-tagged unnatural amino acid
derivative “photo-Leu” 42 and alkyne tag (Fig. 15a and b). Crude
ER microsome fractions were incubated with the probe, irra-
diated, denatured with SDS and ligated to a uorescent azide
derivative by CuAAC. One clear major band was observed at
a molecular weight consistent with that of the hypothesised
target, Sec61a, a subunit of the complex that forms the trans-
location channel at the ER membrane. This target was
conrmed by labelling in microsomes depleted of Sec61a. The
authors concluded that the use of small photo- and click-tags
which presumably minimally perturb the binding of the peptide
to its target, together with the photoreactive properties of the
diazirine, were key factors in the success of this identication
strategy.
The diazirine-functionalised amino acid derivative photo-
methionine 43 has also been reported.97 A third unnatural
diazirine-functionalised amino acid derivative, photo-proline
44, was incorporated into a peptidomimetic with potent anti-
bacterial activity against the Gram-negative bacterium
Pseudomonas aeruginosa (probe 45, Fig. 15).98 The parent pep-
tidomimetic was based on the structure of the naturally
occurring membranolytic host-defense peptide protegrin I. A
forward genetic screen suggested an outer membrane protein
as a potential target, and to conrm direct binding in live cells
the authors synthesised a biotin-functionalised analogue of(b) Falcarinol 51 and inspired probes 52–54.106
This journal is © The Royal Society of Chemistry 2016
Fig. 17 (a) Reaction of iodoacetamide alkyne probes 55 with nucle-
ophilic cysteine residues in proteins.34 (b) Reaction of 4-hydroxy-2-
nonenal (HNE, 56) with cysteine. (c) Caged bromomethyl ketone
electrophilic probe 57 (ref. 109) and alkynyl benziodoxolone reagent
EBX, 58, for labelling cysteines.110 (d) Curcumin-alkyne probe 59 for
compound-centric target identiﬁcation.
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View Article Onlinethe photoreactive peptidomimetic and showed that it did
indeed label the putative target LptD.
Alkyl diazirines have also been incorporated into non-
peptidic compounds. The NP staurosporine (STS) is a potent,
promiscuous kinase inhibitor, which has found use as a general
probe for kinases in diﬀerent technological approaches: an STS
analogue has been directly attached to resin,99 and an aryl azide-
based photocrosslinker and biotin-tagged probe synthesised for
detecting binding partners in cell lysates.100 In order to detect
kinase targets of STS in live cells, Yao and colleagues prepared
an STS analogue 46 with pendant alkyl diazirine and alkyne for
click chemistry (Fig. 15).101 Gel-based uorescence and proteo-
mic analysis of proteins labelled by the STS probe revealed
overlapping but distinct proles in lysates and live cells; ve ‘in
situ-specic’ targets were further validated by pull-down and
Western blot. In addition to the 43 kinases identied in their
approach, the authors also saw a large number of other proteins
in the LC-MS/MS experiments. In this case, the authors chose to
focus on kinases, although they note that kinase-related and
-binding proteins could also be enriched by the probe. The Yao
group expanded on this concept with the report of a series of
versatile ‘minimal’ alkyl-diazirine and alkyne-functionalised
building blocks that can be incorporated into scaﬀolds of
interest.102 They incorporated these into kinase inhibitors,
including STS, and applied a cocktail of several probes to
identify kinases in diﬀerent cell and tissue types. However, in
addition to the 94 kinases identied via the probes from rat
kidney tissues, hundreds of non-kinases were apparently
enriched. Whether these other putative targets represent true
oﬀ-targets of the inhibitors or simply probe-specic background
remained unexplored. This example illustrates a very real
challenge of photoaﬃnity labelling for discovery: how to iden-
tify true binders against a, potentially high, non-specic back-
ground. We discuss this point further in the conclusions, below.
Endogenous small molecules with unknown or unclear
mode of action are also the subject of studies employing PAL.
Acyl-homoserine lactones (e.g. 47) produced by Gram-negative
bacteria are interesting compounds which, in addition to their
roles in bacterial quorum sensing, also trigger responses in
other organisms – such as yeast and human cells.103 The Meijler
group reported a series of alkyne-tagged probes incorporating
a diazirine in diﬀerent positions (48–50 Fig. 16a) and applied
these tools to demonstrate labelling of the known bacterial
target LasR.104 Interestingly, the phenotypic response of bacteria
and human cells to the probes diﬀered – demonstrating that
even the minimal alkyl diazirine modication can have strong
inuences in small molecules. A further example of probes
based on endogenous small molecules is the application of
alkyne- and diazirine-tagged cholesterol analogues to identify
sterol-binding proteins in human cell lines by Cravatt and co-
workers.105 SILAC was used here to quantify enrichment over
control, compare diﬀerent probes and determine sensitivity of
each protein via competition with native cholesterol.
Finally, our group recently applied PAL to identify the
binding partners of the NP falcarinol.106 Falcarinol and the
related NP stipudiol are extracted from vegetables and have
been reported to have anti-cancer properties, but falcarinol isThis journal is © The Royal Society of Chemistry 2016also known to alkylate nucleophiles and isolated proteins.107
Heydenreuter et al. synthesised the NP 51, alkynylated probe 52
and an alkynylated version of the oxidised NP falcarinone 53
(Fig. 16b).106 In situ labelling in A549 cancer cells revealed
a prominent band that was identied by gel-based proteomics
as aldehyde dehydrogenase 2 (ALDH2). To further identify the
possible reversible targets of the NP, the authors synthesised an
alkyne probe 54 incorporating an alkyl diazirine. SILAC and gel-
free MS was used to quantify the targets of the photoprobe.
Several other proteins appeared in this analysis, in addition to
the previously identied covalent target ALDH2; the latter was
further shown to be inhibited by falcarinol in vitro.3 Competitive activity-based protein
screening
3.1 Screening platforms
Historically, ABPP approaches have focused on compounds
bearing electrophilic warheads that react with nucleophilic
residues, oen in enzyme active sites. This has led to the
development of many probes that may preferentially label
a specic enzyme class but are oen quite promiscuous in
labelling multiple proteins within that class. Many of the
studies discussed above make use of competition experimentsNat. Prod. Rep., 2016, 33, 681–708 | 701
Fig. 18 (a) Reaction of lysine in active site of ATP-binding protein with
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View Article Onlineto provide evidence that a probe binds the same target as its
parent compound. Combining these two concepts, small
molecules of interest can be added as competitors to promis-
cuous probes to detect, for example, selective binders.
Competitive ABPP (Fig. 2) has not been very widely applied to
elucidate the mode of action of natural products. However,
given the potential complexity of probe synthesis and the
potential perturbations to function from introducing even
minimal tags into NPs, such approaches are worth considering.
Many promiscuous ABPs preferentially react with cysteine
residues. An example is iodoacetamide-alkyne 55 (Fig. 17),
which has been applied to prole cysteine reactive proteins in
total proteomes.34 Probes based on phenylsulfonate esters,
epoxides, Michael acceptors and a-chloroacetamides all display
proteome reactivity, with a preference for functional reactive
nucleophilic residues.108ATP analogue probe 60.113 (b) NPs geldanamycin 61 and radicicol 62.
Fig. 19 (a) Symplostatin 4 precursor probe 63. (b) E64-inspired
protease probe 64.1143.2 Competitive mode for natural product target elucidation
Competitive ABPP can provide a diﬀerent perspective and an
orthogonal approach for identifying the binding partners of
reactive endogenousmolecules or NPs. The electrophilic lipid 4-
hydroxy-2-nonenal (HNE 56, Fig. 17) has a Michael acceptor
susceptible to reaction with cellular cysteines. Several probes of
HNE have been reported that incorporate an azide or alkyne tag
(see previously). However, in order to rapidly screen for ‘hyper-
reactive’ cysteine residues that could act as cellular redox
sensors by reacting with HNE, Cravatt and co-workers applied
their isoTOP-ABPP (isotopic tandem orthogonal proteolysis
activity-based protein proling) method in combination with
cysteine-reactive iodoacetamide-alkyne (IAA, Fig. 17) for
competitive ABPP.40 isoTOP-ABPP uses heavy or light versions of
an azide-TEV-biotin tag for click chemistry and enrichment of
labelled proteins, allowing comparative quantication of
samples.34 Proteomes of a breast cancer cell line were treated
with lipid electrophiles, including HNE, IAA added and samples
analysed by gel-free MS.40 Of the 1000 cysteines quantied in
the experiments, most were relatively unaﬀected, but a small
subset responded to treatment with the lipids. To further
investigate the susceptibilities of these cysteines, samples were
treated with diﬀerent concentrations of HNE and quantied
relative to DMSO sample (here acting as the standard, by
analogy with the spike-in SILAC approach). In this way, half-
maximal inhibitory concentrations (IC50 values) could eﬀec-
tively be calculated. Follow-up investigations of the hit ZAK
kinase revealed that HNE modication of a specic cysteine
residue inhibited kinase activity. Furthermore, the previously
reported alkyne-HNE 37 (Table 2)93 also labelled this protein,
providing further evidence that it is a target of lipid electro-
philes. The authors discuss the value of applying these two
complementary approaches, noting that the indirect nature of
IAA prolingmeans that the competitor may in fact not bind the
same cysteine as IAA but instead an adjacent residue that is
sterically shielded by probe binding.
IAA is rarely used in living cells, being instead mostly applied
in proteomes due to its high toxicity and the high concentra-
tions required to saturate labelling. The Weerapana group702 | Nat. Prod. Rep., 2016, 33, 681–708recently reported caged bromomethyl ketone probe 57, that is
unreactive and can accumulate in live cells with low toxicity but
is then unmasked by irradiation (Fig. 17).109 57 was used to
prole the eﬀects of EGF stimulation, which enhances
production of reactive oxygen species. Abegg et al. have reported
another generic cysteine-reactive probe for use in live cells
based on alkynyl benziodoxolone and carrying an azide tag for
click chemistry (EBX, 58, Fig. 17).110 This probe proved to be
more reactive than IAA and, although it was still toxic, the
higher reactivity allowed lower concentrations to be used for in
situ labelling. To demonstrate the utility of their probe, and
compare it to IAA, Abegg et al. proled the NP curcumin in
competitive mode. Curcumin is found in the spice turmeric and
has been reported to have anti-cancer and anti-inammatory
properties. The Michael acceptor of curcumin is potentially
cysteine-reactive, and indeed did out-compete select bands in
both IAA and EBX treated samples. SILAC chemical proteomicsThis journal is © The Royal Society of Chemistry 2016
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View Article Onlinewas used to identify those labelled cysteines selectively out-
competed by curcumin, and this was further backed up by
labelling with an alkyne-tagged curcumin derivative 59 (Fig. 17).
Of the 57 targets identied by competitive ABPP, 42 were also
found as targets of 59. The authors also noted that the
complexity of the fragmentation patterns of alkyne-curcumin-
labelled peptides meant that site identication with 59 was very
challenging – whereas identifying the cysteine modication
sites with the simpler IAA or EBX reagents was more straight-
forward. The hits identied with IAA and EBX also did not
overlap completely, highlighting the value of having multiple
reagents available to prole reactive cysteine residues. A further
recent study independently applied the same probe 59 together
with iTRAQ chemical proteomics to identify curcumin targets in
colon cancer cells.111 The authors identied nearly 200 enriched
proteins, adding further evidence that curcumin is a promis-
cuous protein binder.Fig. 20 NP rocaglate 65 and b-lactone-functionalised derivative 66.16
Fig. 21 FluoPOL ABPP screening. (a) If a compound does not bind the pr
highly ﬂuorescently polarised light because the ﬂuorophore tumbles slow
rapidly in solution, resulting in low ﬂuorescence polarisation. Figure adapt
emetine 68.115
This journal is © The Royal Society of Chemistry 2016Probes that are more specic than general cysteine-reactive
compounds for particular subsets of proteins have also been
applied in competitive ABPP. Many cellular proteins bind ATP,
such as kinases and other ATPases; these include the chaperone
HSP90, an important potential drug target in cancer. Nordin
et al. applied an ATP acyl phosphate probe 60,112 which binds to
the ATP pocket and acylates nearby lysine residues with a des-
thiobiotin tag, in vitro (Fig. 18).113 Following enrichment, digest
and LC-MS/MS, labelled peptides were identied directly based
on MS2 fragment spectra, aided by an inclusion list to improve
detection. Competition with ATP was used to distinguish
binding of the probe non-specically to surface exposed lysines
and binding in ATP sites. With this sensitive set-up in place,
Nordin et al. proled the ability of two NPs geldanamycin 61
and radicicol 62 (Fig. 18), as well as several synthetic
compounds, to inhibit HSP90 paralogs via binding to the ATP
pocket. The compounds were applied to live cells and the
authors also searched for oﬀ-targets of the compounds amongst
other ATP-binding proteins.
In 2012, Stolze et al. combined competitive ABPP and uo-
rescent probes to reveal the mode of action of symplostatin 4,
a secondary metabolite from cyanobacteria with potent anti-
malarial activity.114 Symplostatin 4 features a potentially protein-
reactive Michael acceptor and methyl-methoxypyrrolinone (mmp)
unit. SAR studies rst demonstrated the importance of the mmp
unit for anti-parasitic activity, then the authors further charac-
terised the phenotype arising from treatment of the malaria
parasite Plasmodium falciparum with symplostatin 4 and deriva-
tives. They observed a defect in the food vacuole, suggestive ofotein in the assay, the activity-based probe (ABP) can bind, resulting in
ly. (b) In contrast, if a compound binds, the ABP does not and tumbles
ed fromBachovchin et al.115 (c) Fluorophosphonate probe 67 and NP hit
Nat. Prod. Rep., 2016, 33, 681–708 | 703
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View Article Onlinea block in haemoglobin degradation. They synthesised probe 63
(Fig. 19) and used the alkyne tag to attach a rhodamine uo-
rophore. Several proteins were covalently labelled with the
rhodamine dye-coupled symplostatin 4 probe, leading the authors
to hypothesise that proteases called falcipains, which play roles in
parasite development within the red blood cell, were inhibited by
the compound. Competitive labelling experiments using probe 64
based on the epoxide-containing cysteine protease inhibitor E-64
showed that symplostatin 4 inhibited specic members of this
protease family. Quantication of the labelling revealed the
sensitivities of the diﬀerent proteases to the NP.
Competitive ABPP is intuitively most applicable to reactive
NPs. A structural modication that converts an unreactive NP to
a reactive one may change the bioactivity or mode of action, and
so is a risky strategy for target identication. However, there has
always been interest in generating modied versions of NPs and
recently Porco, Cravatt and co-workers studied a derivative of the
NP rocaglate 65 incorporating a reactive b-lactone moiety (66,
Fig. 20).16 Rocaglates have diverse bioactivity and b-lactones have
proven value as electrophilic traps for nucleophilic enzyme resi-
dues.52 Hypothesising that the b-lactone would direct the
compound to enzymes possessing nucleophilic residues, the
authors conducted competitive ABPP against a promiscuous
uorophosphonate probe. SILAC quantication of enriched
proteins with and without competition revealed four out of 40
serine hydrolases that were specically and dose-dependently
inhibited by the novel compound. Competition also worked well
in situ, suggesting that the new rocaglate derivative could serve as
a tool compound for future studies on specic serine hydrolases.
Finally, Cravatt and co-workers developed a high-throughput
competitive screening platform termed uopol-ABPP to screen
an enzyme in vitro for compounds that bind.115 The method
works on the premise that if a relatively large ABP functional-
ised with a uorophore is attached to a protein of interest, the
extent of depolarisation of polarised light emitted by the excited
uorophore will be low. If instead of the probe, a competitor
compound is bound, the probe will be free to tumble rapidly in
solution and will emit depolarised light (Fig. 21). Bachovchin
et al. applied this approach to the putative serine hydrolase
RBBP9. Approximately 18 000 compounds were screened using
RBBP9 and rhodamine-functionalised uorophosphonate
probe 67 that binds serine hydrolases, identifying several hits
including the bioactive natural product emetine 68. Gel-based
uorescence ABPP was further used to rene and study the hits.4 Conclusions
The main strength of chemical proteomics is its ability to
provide an unbiased, global and quantitative analysis of protein
binding partners. By combining a cell-permeable probe with
chemical proteomics, oen facilitated by a two-step bio-
orthogonal ligation protocol, it is possible to work in live cells
(‘in situ’) and with endogenous protein levels. Probes can also be
applied in diverse systems. And using sensitive in-gel uores-
cence detection with well-characterised probes, or using quan-
titative proteomics, it is possible to quantify dose–response,704 | Nat. Prod. Rep., 2016, 33, 681–708response to inhibitor or competitor and even measure IC50 of
probe–protein binding directly in the cell.
These advantages make chemical proteomics a very powerful
method for mode of action studies. However, as with all tech-
nologies, there are limitations and diﬃculties. We have
mentioned many of these in the main part of the review, but in
the following section we will explicitly discuss the main prob-
lems and some potential solutions.4.1 Limitations, pitfalls and potential solutions
One common concern in chemical proteomics that we have
highlighted throughout this review is how to deal with
promiscuity and background binders. There are two issues
here: rstly, at high concentrations, photoreactive and electro-
philic probes will almost always label proteins non-specically
to some extent, and some proteins may be probe-specic hits
(i.e. not targets of the parent compound). Secondly, some
proteins will bind non-specically to aﬃnity resin, and there
may be background from the CuAAC reaction, where used.
The second problem is oen addressed by comparison with
controls combined with quantitative proteomics. However, it can
still be challenging to deal with both highly abundant protein
hits (that may well be present in controls too) and low abundance
proteins that are masked by background. Furthermore, choosing
a cut-oﬀ, even with quantitative data, is diﬃcult. Some resources
are available to help assess whether a putative hit is a ‘sticky’ or
abundant background binder; for example, in one study, the
background binders from diﬀerent resins and aﬃnity enrich-
ment protocols were analysed.116 The issue of background is in
part due to the indirect nature of most chemical proteomics
identication strategies: in general proteins are identied as hits
by their enrichment in probe-treated sample over some control
and not by direct identication of probe modication. As dis-
cussed here, use of a cleavable linker is one approach to this
problem; examples discussed above include identication of the
sites of modication of cysteine-reactive probes,40 the use of
isotopically labelled azide reagents to capture peptides from
proteins labelled with a reactive lipid probe92 and the identi-
cation of sites of aspirin alkylation.79 Such linkers work best with
probes that are incorporated metabolically at dened positions
in a protein or probes that react predictably with certain residues
(e.g. cysteine) and without excessive fragmentation. However,
some of these limitations may be overcome as de novo-aided
sequencing approaches improve and MS instruments become
increasingly sensitive.
The issue of probe promiscuity is diﬃcult to deal with
because it is so context-dependent. Optimising probe concen-
tration and other labelling conditions can sometimes help, and
quantifying enrichment in the presence and absence of
a competitor (typically the parent NP) is one approach widely
used to test whether a protein is a probe-specic hit. This
approach was used to help identify the specic targets of the
NPs zerumbone,91 eupalmerin acetate,89 hypothemicin80 and
mbrolides,85 for example. Multiple probes with modications
at diﬀerent positions can be used to reduce the risk of probe-
related oﬀ-targets and to ensure coverage of as many targets asThis journal is © The Royal Society of Chemistry 2016
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View Article Onlinepossible (an approach used to identify possible targets of aci-
vicin, for example).87 In PAL, choice of photoreactive group may
also have an inuence on the prole of hits, although very few
comparative studies exist, and it can also be challenging to
introduce a photolinker into a small scaﬀold without aﬀecting
compound activity. One recent study analysed the hits of simple
compounds incorporating a benzophenone, aryl azide or alkyl
diazirine photocrosslinker, as well as alkyne tag, with the aim of
providing a list of photolinker-specic targets.117 However, this
study applied gel-based proteomics, which as discussed above
suﬀers from several technical limitations. Further work in this
area may be helpful in providing resources to aid researchers in
assessing whether putative targets are genuine or related to the
photocrosslinker moiety itself. Promiscuity of photoprobes is
a common challenge: as discussed above in the context of
kinase inhibitors, it is diﬃcult to identify ‘true’ binders against
a background of likely probe-specic targets. In our experience,
chemical proteomics experiments, particularly those with
technical challenges (e.g. photocrosslinkers) or where many
proteins are addressed, benet from the following: (1) the
application of quantitative proteomics and rigorous statistical
evaluation of data; (2) control experiments, again performed
quantitatively e.g. competition with parent compound; (3)
follow-up validation of putative targets.
Finally, newly described alternative approaches, such as
CETSA (cellular thermal shi assay)118 or TPP (thermal pro-
teome proling),119 for measuring compound–protein binding
in cells complement chemical proteomics and are more readily
applicable to compounds with non-covalent binding modes.
CETSA or TPP relies on the fact that binding of a compound
oen stabilises the target protein in a manner that can be
detected by a shi in the melting temperature of that protein.
Thus, lysates or cells are treated with a compound, and sample
aliquots heated to diﬀerent temperatures; the aliquots are then
lysed if necessary and centrifuged to remove aggregated
(denatured) proteins; the soluble portion is analysed to detect
the amount of undenatured protein remaining. These
approaches are only applicable to protein–ligand interactions
showing a thermal shi and, currently, to soluble proteins, but
are nonetheless very powerful.
Linking target binding with bioactivity, and dealing with
pleiotropic eﬀects are broad challenges faced by any approach
that seeks to identify the proteins that NPs bind. Structure–
activity relationship studies (e.g. comparing the eﬀects of
compounds with diﬀerent levels of bioactivity) and in-depth
biological characterisation are typically used for this next level
of mode-of-action deconvolution.4.2 Current and future challenges
In 2012, Moellering and Cravatt proposed that chemical pro-
teomics can help bridge the gulf between early drug discovery
eﬀorts that focus on identifying interesting drug targets, oen
genetically, and later eﬀorts where the emphasis is on the
chemistry or pharmacology of small molecules.120 They note
that chemical probes provide a way to detect engagement of
a compound with its target protein in living systems, andThis journal is © The Royal Society of Chemistry 2016suggest that this strength could be leveraged to bring chemistry-
driven approaches into contact with early stages of drug
discovery – validating drug targets chemically, identifying novel
druggable proteins, and clarifying the mode of action of
compounds identied in phenotypic screens. Although chem-
ical proteomics has made huge contributions to our under-
standing of particular enzyme classes, large portions of the
proteome, and many organisms, remain unexplored. It is also
interesting that most clinically approved drugs target
membrane receptors,121 but that relatively few chemical probes
have been developed to address this large class of proteins.
Aﬃnity chromatography and chemical proteomics in cell
lysates are diﬃcult to apply to membrane proteins since cell
lysis, particularly if detergents are used, can seriously disrupt
these proteins. Other techniques such as CETSA/TPP also
currently cannot address membrane proteins. However, in situ
chemical probes should, in principle, be applicable to capturing
membrane targets. Nevertheless, the vast majority of in situ
chemical probes reported so far target either enzymes with fairly
well-dened pockets (proteases, kinases) or are promiscuous
electrophiles that bind soluble metabolic enzymes; this is likely
due to the eld's historical focus on activity-based probes.
Several photoaﬃnity natural product-based probes that target
membrane proteins have been reported, including mimics of
vancomycin and a peptidomimetic, but the number of examples
is still small. The lack of chemical probes targeting membrane
receptors may be due to the facts that these proteins typically
bind ligands non-covalently (necessitating the use of photo-
reactive probes or probes designed to react with a non-catalytic
nucleophile in the binding pocket), oen have multiple active
and inactive conformations complicating ligand binding, and are
typically of low abundance. As illustrated by the examples given
above, with photoaﬃnity labelling it is particularly challenging to
tease out true targets against background labelling, and this may
have thus far hindered the development of probes for low
abundance membrane receptors. However, in situ chemical pro-
teomics is uniquely positioned to tackle this challenge. Improved
sensitivity of mass spectrometry instrumentation may aid in the
detection of low abundance hits or allow lower concentrations of
probe to be used (which can reduce non-specic binding and
hence oﬀ-targets) and focused eﬀorts to mine chemical space
should yield more specic high aﬃnity probes. Design of cova-
lent probes for G-protein coupled receptors is also an active area
of research, for example.122 Natural products provide a rich
resource of potential probes that could be applied in underex-
plored areas of chemical proteomics.
Chemical proteomics, by its nature, focuses on proteins, but
small molecules also act on other biomolecules (DNA, RNA) or
structures (membranes). However, many of the same principles
of chemical proteomics could be developed for direct detection of
binding of small molecules to oligonucleotides. For example,
clickable Pt(II)-complexes were used to identify rRNA interactors
of the drug picoplatin in Saccharomyces cerevisiae.123 Studies
applying such complexes were recently reviewed by White et al.124
Finally, the indirect nature of many identication strategies
is a limitation that we have discussed in depth here. However,
cleavable linkers and advances in quantitative proteomicNat. Prod. Rep., 2016, 33, 681–708 | 705
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View Article Onlinetechnology continue to improve. We anticipate that eﬀorts to
make these technologies more broadly applicable and the
development of innovative tools will continue to be at the
cutting edge of chemical proteomics.
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